mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer.

Polybromo-1 () gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.